Genexine Inc 095700
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 42.96
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Genexine Inc is a clinical-stage biotechnology company. It is focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technologies are Therapeutic DNA vaccine technology and Hyfc platform. The company's product pipeline includes products such as GX-H9, GX-E2, GX-G3, GX-G6, and Papitrol-188 among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 80
- Website
- http://www.genexine.com
Comparables
Valuation
|
Metric
|
095700
|
310210
|
196170
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 670.41 |
Price/Book Value | 0.96 | 30.68 | 96.41 |
Price/Sales | 42.96 | 2,285.28 | 194.60 |
Price/Cash Flow | — | — | 3,895.39 |
Price/Earnings
095700
310210
196170
Financial Strength
|
Metric
|
095700
|
310210
|
196170
|
|---|---|---|---|
Quick Ratio | 1.11 | 4.09 | 1.62 |
Current Ratio | 1.23 | 4.14 | 1.67 |
Interest Coverage | −13.75 | −27.69 | −10.35 |
Quick Ratio
095700
310210
196170
Profitability
|
Metric
|
095700
|
310210
|
196170
|
|---|---|---|---|
Return on Assets (Normalized) | −13.03% | −43.61% | −0.85% |
Return on Equity (Normalized) | −17.52% | −80.68% | −1.46% |
Return on Invested Capital (Normalized) | −12.96% | −47.75% | −3.30% |
Return on Assets
095700
310210
196170
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Dbrdlntv | Ypbt | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Wkwjqkdlt | Tsdrcyz | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xhkjntmk | Gsbzbqx | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jzmfkjrn | Yrmjg | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Rmljvkb | Nzws | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Xczvvgzyk | Msxq | $28.1 Bil | |||
| Moderna Inc
MRNA
| Tmvwrwcr | Fqxf | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Cnkfndp | Zdc | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Jmxwlrn | Shwfjr | $13.4 Bil | |||
| Incyte Corp
INCY
| Dlgvxgb | Xsrfxz | $12.7 Bil |
United States